Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
83.45
-0.69 (-0.82%)
At close: Dec 20, 2024, 4:00 PM
84.32
+0.87 (1.04%)
After-hours: Dec 20, 2024, 4:09 PM EST
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for ITCI stock have an average target of 97.67, with a low estimate of 74 and a high estimate of 130. The average target predicts an increase of 17.04% from the current stock price of 83.45.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 4, 2024.
Analyst Ratings
The average analyst rating for ITCI stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
Buy | 5 | 4 | 4 | 5 | 5 | 5 |
Hold | 2 | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 12 | 11 | 11 | 12 | 12 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JP Morgan | JP Morgan | Buy Maintains $81 → $89 | Buy | Maintains | $81 → $89 | +6.65% | Nov 4, 2024 |
Needham | Needham | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +19.83% | Oct 31, 2024 |
Needham | Needham | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +19.83% | Oct 30, 2024 |
Morgan Stanley | Morgan Stanley | Buy Maintains $92 → $95 | Buy | Maintains | $92 → $95 | +13.84% | Oct 11, 2024 |
RBC Capital | RBC Capital | Buy Maintains $106 → $108 | Buy | Maintains | $106 → $108 | +29.42% | Oct 4, 2024 |
Financial Forecast
Revenue This Year
688.47M
from 464.37M
Increased by 48.26%
Revenue Next Year
953.21M
from 688.47M
Increased by 38.45%
EPS This Year
-0.71
from -1.46
EPS Next Year
0.28
from -0.71
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 715.1M | 1.1B | 1.7B | |||
Avg | 688.5M | 953.2M | 1.4B | |||
Low | 652.2M | 839.9M | 1.1B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 54.0% | 57.9% | 79.5% | |||
Avg | 48.3% | 38.5% | 48.4% | |||
Low | 40.4% | 22.0% | 15.5% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -0.37 | 1.39 | 6.33 | |||
Avg | -0.71 | 0.28 | 3.64 | |||
Low | -1.04 | -0.92 | 1.46 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | 2,182.1% | |||
Avg | - | - | 1,210.7% | |||
Low | - | - | 426.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.